Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Quest Diagnostics To Plunge 16%? Here Are 5 Other Price Target Changes For Thursday

Published 17/11/2022, 12:35
© Reuters.  Quest Diagnostics To Plunge 16%? Here Are 5 Other Price Target Changes For Thursday
DGX
-
TGTB34
-
Q1UE34
-

Benzinga -

  • Citigroup (NYSE:C) cut Quest Diagnostics Incorporated (NYSE: NYSE:DGX) price target from $145 to $125. . Citigroup analyst Patrick Donnelly downgraded the stock from Neutral to Sell. Quest Diagnostics shares rose 0.9% to close at $149.27 on Wednesday.
  • Deutsche Bank (ETR:DBKGn) cut the price target on Target Corporation (NYSE: NYSE:TGT) from $183 to $144. Deutsche Bank analyst Paul Trussell downgraded the stock from Buy to Hold. Target shares fell 0.2% to $155.24 in pre-market trading.
  • HC Wainwright & Co. cut Repare Therapeutics Inc. (NASDAQ: RPTX) price target from $38 to $25. HC Wainwright & Co. analyst Robert Burns maintained a Buy rating on the stock. Repare Therapeutics shares fell 0.6% to close at $17.00 on Wednesday.
  • Morgan Stanley (NYSE:MS) raised Principal Financial Group, Inc. (NASDAQ: PFG) price target from $76 to $79. Morgan Stanley analyst Nigel Dally downgraded the stock from Equal-Weight to Underweight. Principal Financial fell 1.6% to $91.47 in pre-market trading.
  • Truist Securities cut Advance Auto Parts, Inc. (NYSE: AAP) price target from $228 to $147. Truist Securities analyst Scot Ciccarelli downgraded the stock from Buy to Hold. Advance Auto Parts shares fell 1.3% to $154.17 in pre-market trading.
  • Credit Suisse (SIX:CSGN) slashed Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) price target from $20 to $14. Credit Suisse analyst Benjamin Chaiken downgraded the stock from Outperform to Underperform. Norwegian Cruise Line shares fell 5% to $16.72 in pre-market trading.
Check out this: Super Micro Computer, Ryan Specialty And This Technology Stock Insiders Are Buying

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.